Cenkos Securities Ltd reiterated their buy rating on shares of Cello Group plc (LON:CLL) in a research report report published on Wednesday.

Separately, Peel Hunt reissued a buy rating and set a GBX 130 ($1.70) price objective on shares of Cello Group plc in a research note on Thursday, June 23rd.

Shares of Cello Group plc (LON:CLL) opened at 107.60 on Wednesday. Cello Group plc has a 12 month low of GBX 77.10 and a 12 month high of GBX 115.00. The company’s market cap is GBX 93.55 million. The company’s 50 day moving average price is GBX 104.04 and its 200 day moving average price is GBX 97.59.

The company also recently declared a dividend, which will be paid on Friday, November 4th. Shareholders of record on Thursday, October 6th will be given a dividend of GBX 1 ($0.01) per share. The ex-dividend date is Thursday, October 6th. This represents a yield of 0.94%.

About Cello Group plc

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.